5HB Stock Overview
Shanghai Haohai Biological Technology Co., Ltd. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
Shanghai Haohai Biological Technology Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$3.30 |
| 52 Week High | HK$4.70 |
| 52 Week Low | HK$2.60 |
| Beta | 0.76 |
| 11 Month Change | -4.07% |
| 3 Month Change | -7.82% |
| 1 Year Change | -4.94% |
| 33 Year Change | -18.23% |
| 5 Year Change | -7.60% |
| Change since IPO | -25.66% |
Recent News & Updates
Recent updates
Shareholder Returns
| 5HB | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -2.4% | 1.1% | 1.3% |
| 1Y | -4.9% | -18.5% | 7.9% |
Return vs Industry: 5HB exceeded the German Biotechs industry which returned -18.8% over the past year.
Return vs Market: 5HB underperformed the German Market which returned 7.2% over the past year.
Price Volatility
| 5HB volatility | |
|---|---|
| 5HB Average Weekly Movement | 8.0% |
| Biotechs Industry Average Movement | 6.7% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 5HB's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 5HB's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 2,179 | Jianying Wu | www.3healthcare.com |
Shanghai Haohai Biological Technology Co., Ltd. engages in the research, development, manufacture, and sale of biomedical materials in China, Europe, the United States, and internationally. The company offers ophthalmology products consisting intraocular lens, medical sodium hyaluronate gel, and lubricant eye drop.
Shanghai Haohai Biological Technology Co., Ltd. Fundamentals Summary
| 5HB fundamental statistics | |
|---|---|
| Market cap | €1.70b |
| Earnings (TTM) | €56.27m |
| Revenue (TTM) | €359.28m |
13.8x
P/E Ratio2.2x
P/S RatioIs 5HB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 5HB income statement (TTM) | |
|---|---|
| Revenue | CN¥2.75b |
| Cost of Revenue | CN¥848.86m |
| Gross Profit | CN¥1.90b |
| Other Expenses | CN¥1.47b |
| Earnings | CN¥430.21m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.87 |
| Gross Margin | 69.10% |
| Net Profit Margin | 15.66% |
| Debt/Equity Ratio | 7.0% |
How did 5HB perform over the long term?
See historical performance and comparison